Evidence map›Paper›PMID 22147248›Full record

ArticleDigestive diseases and sciences2012

Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls.

Mustafa Erhan Altunöz, Ebubekir Senateş, Atakan Yeşil, Turan Calhan, Ayşe Oya Kurdaş Ovünç

Abstract readControlled Clinical Trial
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Article
  18. Update on Vaccinating the Patient With Inflammatory Bowel Disease.Current treatment options in gastroenterology · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mustafa Erhan AltunözDepartment of Gastroenterology, Haydarpaşa Numune Education and Research Hospital, Tibbiye Cad. No:40, 34668 Üsküdar, Istanbul, Turkey. erhanaltunoz@hotmail.com
Ebubekir Senateş
Atakan Yeşil
Turan Calhan
Ayşe Oya Kurdaş Ovünç
Haydarpaşa Numune Eğitim ve Araştırma Hastanesi · TRÜmraniye Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B (HBV) is a vaccine-preventable infection that may cause severe infections, particularly in patients who are being treated with immunosuppressive therapy [(i.e., inflammatory bowel disease (IBD)]. Limited data are available about IBD patients' response rate to HBV vaccine.

aimTo assess the efficacy of HBV vaccine in IBD patients and healthy controls.

methodsSerological markers of HBV were assessed in IBD patients, and HBV vaccine was administered to seronegative patients. The subsequent determination of anti-HBs antibody was recorded. An adequate immune response (AIR) and an effective immune response (EIR) to HBV were defined as more than 10 and 100 mIU/ml, respectively. The single dose vaccine was administered at 0, 1 and 6 months.

resultsA total of 102 patients with IBD (39 Crohn's disease, 63 ulcerative colitis; 54 female, 48 male) and 52 (25 female, 27 male) healthy controls were included. Mean age for patients and controls were 38 ± 12 and 31 ± 8, respectively (P < 0.001). Both AIR and EIR were significantly lower in patients than in controls (P < 0.001), but they were similar between patients with CD and UC (P = 0.302). Forty-four (43%) patients were on immunosuppressive therapy before vaccination. After vaccination, 76 and 53% of the patients had AIRs and EIRs, respectively, whereas 100 and 87% of the controls had AIRs and EIRs, respectively (P < 0.001 and P < 0.001, respectively).

conclusionsThe response rate of IBD patients receiving HBV vaccinations were significantly lower compared to controls. The response rate of those receiving immunosuppressive therapy and with active disease was much too low. Vaccination should be given during remission and at immunosuppression-free times.

Indexed as

AdultAntibody FormationColitis, UlcerativeColonCrohn DiseaseFemaleHepatitis B AntibodiesHepatitis B VaccinesHumansIleumImmunization ScheduleImmunosuppressive AgentsMaleHepatitis B AntibodiesHepatitis B VaccinesImmunosuppressive Agents

Identifiers

PMID22147248
OpenAlexW2087544958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.